Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX® (moxifloxacin HCl) for a new use ...

It is a fluoroquinolone antibacterial indicated for treating infections in adults Lupin’s US subsidiary, Gavis Pharmaceuticals has received tentative approval for its Moxifloxacin Hydrochloride ...

The antibiotic Avelox may be linked to a rare but potentially life-threatening liver injury, Health Canada warns. Avelox, or moxifloxacin, is used to treat a broad spectrum of bacterial infections, ...

Dec. 19, 2005 —Australia's Therapeutic Goods Administration has approved anecortave acetate 15-mg suspension for depot injection in the treatment of subfoveal choroidal neovascularization due to ...

KENILWORTH, N.J. – AVELOX (moxifloxacin HCl) monotherapy at 400 mg once daily is as effective as the high-dose combination of levofloxacin (500 mg twice daily) plus ceftriaxone (2 g once daily) in ...

The Food and Drug Administration (FDA) has approved Avelox (moxifloxacin; Bayer) for the treatment of pneumonic and septicemic plague, and for the prevention of plague in adults. Avelox is a quinolone ...

On May 8, 2015, FDA approved a new antibacterial treatment for plague, Avelox ® (moxifloxacin). Plague is a deadly infectious disease caused by the enterobacteria Yersinia pestis, which can be spread ...

FRANKFURT, Feb 14 (Reuters) - Bayer is sending letters warning doctors in Europe of rare incidents of severe liver and skin side effects in patients taking its Avelox antibiotic, the German drugs and ...

Bayer is celebrating the news that a US court has ruled in its favour in a patent dispute concerning the German firm’s big-selling antibiotic Avelox. Bayer is celebrating the news that a US court has ...

Dr Reddy's Laboratories Ltd has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of a wide range of diseases, including pneumonia, bronchitis and skin infections.The drug ...

DALLAS--(BUSINESS WIRE)--The Dallas-based national law firm of Baron & Budd, P.C., a leader in pharmaceutical litigation, has filed the first lawsuit involving a form of nerve damage known as ...